Articles published by AstraZeneca
FLUMIST approved for self-administration in the US
September 20, 2024
From AstraZeneca
Via Business Wire
Tickers
AZN
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
September 18, 2024
From AstraZeneca
Via Business Wire
Tickers
AZN
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
September 03, 2024
From AstraZeneca
Via Business Wire
Tickers
AZN
AstraZeneca’s H1 and Q2 2024 Financial Results
July 25, 2024
From AstraZeneca
Via Business Wire
Tickers
AZN
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
May 21, 2024
From AstraZeneca
Via Business Wire
Tickers
AZN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|